The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

Changes in your skin texture might be warning signs of internal health problems long before other symptoms show up.

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

A doctor has shed some light on why itchy rashes sometimes mysteriously appear on the body - and what you need to do ...

Urticaria, commonly known as hives ... on the skin. These welts can vary in size and often change shape or location, making the experience somewhat unpredictable. Understanding the causes ...

Skin rashes can have many different causes, one of which is medications ... A drug rash, or a skin reaction to a drug, can appear as discoloration, bumps, blisters, urticaria (hives), itching, or ...